HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma
Clinical trial NCT05821361 · UNKNOWN
Trial details
- NCT number
- NCT05821361
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-01
- Primary completion
- 2024-08-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.